Problems with Drug-Eluting Coronary Stents — The FDA Perspective
N. I. Muni
and
T. P. Gross
- 14 Oct, 2004
This article requires a subscription.
Login via Athens or your institution
Already a print subscriber? Activate your online access
Not a Subscriber?
